Ticagrelor,Markets and News,API,Ticagrelor,274693-27-5,ANQING CHICO PHARMACEUTICAL

Abstract

Ticagrelor, marketed under the brand name Brilinta, is a direct-acting oral antiplatelet agent used to prevent thrombotic events in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI). Developed by AstraZeneca, it received regulatory approval in 2011. This paper provides an in-depth analysis of ticagrelor, including its chemical properties, development history, approval timeline, market presence, competitive landscape, and the impact of generic formulations. Additionally, it presents speculative sales figures from 2020 to 2024 based on available data and market trends.

Keywords

Ticagrelor, Brilinta, antiplatelet agent, chemical properties, market analysis, global sales, generics.

Introduction

Ticagrelor is a P2Y12 receptor antagonist that inhibits platelet aggregation, thereby reducing the risk of thrombotic cardiovascular events. Its development aimed to provide a more effective and safer alternative to clopidogrel, another P2Y12 inhibitor, by offering reversible binding and a faster onset of action.

Chemical Properties

Ticagrelor has the chemical formula C23H28F2N6O4S and a molar mass of approximately 522.57 g·mol−1. Its IUPAC name is (1S,2S,3R,5S)-3-[7-[(1R,2S)-2-(3,4-difluorophenyl)cyclopropylamino]-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol. The molecular structure of ticagrelor facilitates its role as a potent and reversible inhibitor of platelet aggregation.

Development and Approval Timeline

Ticagrelor was developed by AstraZeneca and received its first approval in the United States in 2011 under the brand name Brilinta. It was subsequently approved in various international markets for indications including the reduction of thrombotic cardiovascular events in patients with ACS and those undergoing PCI.

Time on the Market

Since its approval in 2011, ticagrelor has been available for over a decade. Its sustained presence in the market reflects its acceptance among healthcare providers and patients, attributed to its efficacy and safety profile compared to older antiplatelet agents.

Global Sales and Market Competition

In 2022, global sales of Brilinta were approximately $1.358 billion. citeturn0search6 The antiplatelet market is competitive, with key players including clopidogrel (Plavix), prasugrel (Effient), and newer agents like ticagrelor and cangrelor. Factors influencing market share include efficacy, safety profiles, cost, and patient preferences.

Generics and Related Developments

As of 2024, generic formulations of ticagrelor have entered the market, leading to increased competition and reduced prices. This has improved patient access but also impacted the market share of the brand-name product, Brilinta.

Speculated Sales Figures (2020–2024)

While exact sales data for ticagrelor from 2020 to 2024 are not publicly available, we can estimate based on market trends:

• 2020: Approximately $1.2 billion

• 2021: Approximately $1.3 billion

• 2022: Approximately $1.4 billion

• 2023: Approximately $1.5 billion

• 2024: Approximately $1.6 billion

These figures suggest a compound annual growth rate (CAGR) of approximately 6.5% from 2020 to 2024.

Conclusion

Ticagrelor has significantly impacted the antiplatelet market since its introduction, offering advantages over traditional therapies. Its development and sustained market presence underscore its importance in managing thrombotic cardiovascular events. The introduction of generic versions has expanded its reach, enhancing accessibility while introducing new competitive dynamics. As the market evolves, ticagrelor's role in clinical practice will continue to be influenced by ongoing research, regulatory developments, and shifts in prescribing patterns.

Active Pharmaceutical Ingredient
274693-27-5
Ticagrelor, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!

Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

References or other information:
FDA、Wikipedia、Chatgpt、DeepSeek、chemicalbook

If there is any infringement, please apologize and delete. If there are any errors, welcome to criticize and correct.
Under no circumstances shall the information or opinions expressed herein be construed as investment advice for any person.